Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2018 Apr 21

PMID 29675110

Citations 10

Authors

Sumin Guo

Michael G Martin

Cheng Tian

Jinglin Cui

Lishi Wang

Shucai Wu

Weikuan Gu

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the deadliest cancer in the world. Angiogenesis plays a crucial role of the incidence, progression, and metastasis in lung cancer. Angiogenesis inhibitors are used to treat non-small cell lung cancer (NSCLC) patients, and the molecular biomarkers are also being assessed to predict treatment response/therapeutic response and patients' prognosis. Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates angiogenesis. Due to its predictive values of prognosis on NSCLC, a large number of methods have been developed and evaluated to detect VEGF levels in a variety of studies. In this article, we review the detection methods designed to measure the VEGF levels in different body fluids and prognosticate the value of VEGF in treatment, diagnosis and survival in lung cancer.

Citing Articles

Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.

Jarry U, Bostoen M, Archambeau J, Pineau R, Chaillot L, Jouan F PLoS One. 2024; 19(6):e0304914.

PMID: 38935790 PMC: 11210880. DOI: 10.1371/journal.pone.0304914.

Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022.

Ke S, Chen S, Jiang Y, Gong H, Yu J, Li X Cancer Innov. 2023; 2(4):265-282.

PMID: 38089746 PMC: 10686150. DOI: 10.1002/cai2.74.

Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis.

Feng X, Muller D, Zahed H, Alcala K, Guida F, Smith-Byrne K EBioMedicine. 2023; 92:104623.

PMID: 37236058 PMC: 10232655. DOI: 10.1016/j.ebiom.2023.104623.

The relationship of vascular endothelial growth factor and osteopontin expression with 3-year progression-free survival of locally advanced nasopharyngeal cancer patients treated with platinum-based chemoradiation.

Irawan C, Nufus H, Rachmadi L, Harimurti K, Munandar A, Yunus R Contemp Oncol (Pozn). 2022; 26(3):220-228.

PMID: 36381664 PMC: 9641634. DOI: 10.5114/wo.2022.120698.

Elevated serum Cripto-1 and VEGF levels in patients with non-small cell lung cancer.

Xu C, Zou J, Li L, Yuan Q, Wang W FASEB Bioadv. 2022; 4(8):539-546.

PMID: 35949510 PMC: 9353448. DOI: 10.1096/fba.2022-00002.

References

Pallaud C, Reck M, Juhasz E, Szima B, Yu C, Burdaeva O . Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. Lung Cancer. 2014; 86(1):67-72. DOI: 10.1016/j.lungcan.2014.07.019. View

Suto K, Yamazaki Y, Morita T, Mizuno H . Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem. 2004; 280(3):2126-31. DOI: 10.1074/jbc.M411395200. View

Otrock Z, Mahfouz R, Makarem J, Shamseddine A . Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis. 2007; 39(2):212-20. DOI: 10.1016/j.bcmd.2007.04.001. View

Tordjman R, Ortega N, Coulombel L, Plouet J, Romeo P, Lemarchandel V . Neuropilin-1 is expressed on bone marrow stromal cells: a novel interaction with hematopoietic cells?. Blood. 1999; 94(7):2301-9. View

Soker S, Takashima S, Miao H, Neufeld G, Klagsbrun M . Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92(6):735-45. DOI: 10.1016/s0092-8674(00)81402-6. View

Poon R, Fan S, Wong J . Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001; 19(4):1207-25. DOI: 10.1200/JCO.2001.19.4.1207. View

Volm M, Koomagi R, Mattern J . Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 1997; 74(1):64-8. DOI: 10.1002/(sici)1097-0215(19970220)74:1<64::aid-ijc11>3.0.co;2-i. View

Yuan A, Yu C, Luh K, Kuo S, Lee Y, Yang P . Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol. 2002; 20(4):900-10. DOI: 10.1200/JCO.2002.20.4.900. View

Akahane M, Akahane T, Matheny S, Shah A, Okajima E, Thorgeirsson U . Vascular endothelial growth factor-D is a survival factor for human breast carcinoma cells. Int J Cancer. 2005; 118(4):841-9. DOI: 10.1002/ijc.21420. View

10.

Liu J, Liu Y . Influence of erbanxiao solution on inhibiting angiogenesis in stasis toxin stagnation of non-small cell lung cancer. J Tradit Chin Med. 2013; 33(3):303-6. DOI: 10.1016/s0254-6272(13)60169-7. View

11.

Delmotte P, Martin B, Paesmans M, Berghmans T, Mascaux C, Meert A . [VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. Rev Mal Respir. 2002; 19(5 Pt 1):577-84. View

12.

Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M . VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999; 154(5):1381-90. PMC: 1866582. DOI: 10.1016/S0002-9440(10)65392-8. View

13.

Horn L, Dahlberg S, Sandler A, Dowlati A, Moore D, Murren J . Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009; 27(35):6006-11. PMC: 2793043. DOI: 10.1200/JCO.2009.23.7545. View

14.

Zhan P, Wang J, Lv X, Wang Q, Qiu L, Lin X . Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009; 4(9):1094-103. DOI: 10.1097/JTO.0b013e3181a97e31. View

15.

Keith R, Miller Y, Gemmill R, Drabkin H, Dempsey E, Kennedy T . Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res. 2000; 6(5):1616-25. View

16.

Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S . Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer. 2005; 92(7):1231-9. PMC: 2361974. DOI: 10.1038/sj.bjc.6602481. View

17.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

18.

Shingyoji M, Ando S, Nishimura H, Nakajima T, Ishikawa A, Itakura M . VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel. Anticancer Res. 2009; 29(7):2635-9. View

19.

Zhao P, Bu X, Wei X, Sun W, Xie X, Li C . Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. Int Immunopharmacol. 2015; 25(2):450-6. DOI: 10.1016/j.intimp.2015.02.010. View

20.

Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M . Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 2002; 62(23):7124-9. View